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Structured Abstract 
Background 
Transcatheter aortic valve implantation (TAVI) is now established as an alternative 
treatment to surgical aortic valve replacement. Data examining the impact of dialysis 
on outcomes after TAVI are lacking.  
Objectives 
To determine the risk factors for post-TAVI dialysis and to determine the impact of 
pre-TAVI or post-TAVI dialysis on mortality.  
Methods 
The UK TAVI Registry was established to report outcomes on all TAVI procedures 
performed within the United Kingdom (2007-2014). Data was collected prospectively 
on 6464 patients with a median follow-up of  625 days. 
Results 
The proportion of patients on dialysis before TAVI has remained constant at 1.8%. 
After TAVI, the proportion of patients newly needing dialysis after TAVI  has fallen 
from 6.1% (2007/8) to 2.3% (2013/4). The risk of new dialysis requirement after 
TAVI was independently associated with lower baseline renal function, year of 
procedure, impaired left ventricular function, diabetes, use of an Edwards valve, a 
non-transfemoral approach, need for open surgery and moderate to severe aortic 
regurgitation after the procedure. Requirement for new dialysis after TAVI was 
associated with higher mortality at 30 days (Hazard Ratio (HR) 6.44; 95% Confidence 
Intervals (CI) 4.87-8.53) and at four years (HR 3.54; 95%CI 2.99-4.19; P<0.001 for 
all) compared to patients without dialysis requirement.  
Conclusions 
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The proportion of patients needing dialysis after TAVI has decreased over time. Post-
TAVI dialysis is associated with increased mortality.  Factors identified with dialysis 
requirement after TAVI require further investigation. 
 
Key words: mortality, acute kidney injury, valve type 
 
 
Condensed Abstract 
 
Outcomes after TAVI in relation to dialysis requirements were examined in 6464 
patients from the UK TAVI Registry. The proportion of patients on dialysis before 
TAVI has remained constant (1.8%), whereas the proportion newly needing dialysis 
has fallen from 6.1% (2007/8) to 2.3% (2013/4). The risk of new dialysis requirement 
was associated with lower eGFR, year, impaired LV function, diabetes, use of an 
Edwards valve, non-transfemoral approach, need for open surgery and moderate-to-
severe aortic regurgitation post-procedure. Requirement for new dialysis after TAVI 
was associated with higher mortality at 30 days and at 4 years (P<0.001 for both). 
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Abbreviations 
 
AKI – acute kidney injury 
CI – confidence intervals 
CKD – chronic kidney disease 
CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration 
eGFR – estimated glomerular filtration rate 
HR – hazard ratio 
NICOR – National Institute of Cardiovascular Outcomes Research 
OR – odds ratio 
SAVR – surgical aortic valve replacement 
TAVI – Trans-catheter aortic valve implantation 
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INTRODUCTION 
Trans-catheter aortic valve implantation (TAVI) is now established as an effective 
treatment for patients with severe symptomatic aortic stenosis at high risk from a 
conventional cardiac surgical aortic valve replacement (SAVR).  Factors such as 
advanced age, frailty, or high co-morbidity are used routinely to identify patients at 
high or, in selected cases, intermediate risk patients who might be better treated by 
TAVI rather than SAVR.(1) Worldwide, the use of TAVI is accelerating as registry 
and trial data indicate good medium term outcomes; over 100,000 procedures have 
now been performed.(2)   
 
The prevalence of pre-procedural renal dysfunction in patients undergoing TAVI is 
high (50-60% with chronic kidney disease (CKD) stage 3 or worse)(3,4) and has been 
shown to be significantly associated with increased mortality(3,4) and acute kidney 
injury (AKI)(5) post-TAVI. However, although the reported new need for dialysis 
after TAVI has been examined in several studies,(6-22) most are single centre and 
report data on less than 300 patients with rates for post-procedure dialysis varying 
between 0% and 21%. A recent meta-analysis examining the impact of acute kidney 
injury (AKI) after TAVI analysed 13 studies and reported a rate of new dialysis of 
5.8% (89 of 1528 patients).(5) A high (9-fold increase) mortality at 1 year associated 
with the need for dialysis after TAVI was reported in a single study of 270 
subjects.(16) Data from the German TAVI-registry also suggested new dialysis 
requirement after TAVI was associated with higher mortality at 30-days but not at 1-
year.(23) To the best of our knowledge no study has yet compared outcomes of 
patients requiring dialysis support after TAVI with those already on dialysis before 
the procedure. 
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Given the wide variation in the reported rates of dialysis after TAVI and the 
potentially very high mortality associated with this complication, there is a need for 
better information based upon larger data sets. Such data sets might also provide a 
better understanding of the risk factors associated with the need for post procedural 
dialysis allowing the design of preventative strategies. The objectives of this study 
were to firstly define the incidence of dialysis requirement after TAVI in the UK, 
secondly to determine pre-procedural and peri-procedural factors associated with the 
need for dialysis after TAVI and thirdly, to compare outcomes in patients requiring 
dialysis after TAVI with subjects already established on dialysis and those without 
any dialysis requirement. 
 
METHODS 
 
The database 
The UK TAVI Registry has collected data on all TAVI procedures performed in the 
UK since 2007.  The registry is managed by the National Institute for Cardiovascular 
Outcomes Research (NICOR) with clinical direction and strategy provided by the UK 
TAVI steering group (established in 2008).  The UK TAVI dataset is collected using 
the web based interface from NICOR as previously described.(24) Case ascertainment 
is performed by comparing the centre’s reported numbers of total procedures with the 
number of procedures uploaded to the NICOR. The national dataset between 2007 
and 2014 was provided by NICOR to the investigators.  Range checks to look for 
extreme values and assessments of internal consistency were applied during upload. 
All data including peri-procedural complications and complications up to hospital 
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discharge were self-reported according to the definitions within the national 
dataset.(1) Centres providing records with missing, extreme or inconsistent values 
were contacted and asked to check and modify records as appropriate. The pre-
procedure estimated glomerular filtration rate (eGFR) was calculated using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula with serum 
creatinine recalibrated to be traceable to an isotope-derived mass spectroscopy 
method.(25) Patients not requiring dialysis support before the TAVI procedure were 
divided into five groups of GFR categories based on the widely used clinical 
classification(26): ≥ 60 (eGFR category>60); 45-59 (CKD stage 3a); 30-44 (CKD 
stage 3b); 15-29 (CKD stage 4); and <15 mL/min1.73 m2 (CKD stage 5) Patients 
were also divided in to 3 groups depending on their dialysis requirements: patients 
who required dialysis before the TAVI procedure; those who newly required dialysis 
support after the TAVI procedure and those who did not require dialysis support 
either before or after the TAVI procedure.  
Mortality tracking 
A robust independent system for tracking mortality exists in England and Wales (two 
of the four countries in the United Kingdom covering 89% of the total UK 
population). The National Health Service Central Register performed case linkage to 
data held by the Office of National Statistics in May 2015 using each patient’s unique 
National Health Service Number. Validated life status was available in 6464 of 7364 
patients (88%) who underwent a TAVI procedure between 1st January 2007 and 31st 
December 2014 consistent with proportion of patients from England and Wales. This 
cohort was used for all the survival analyses. All patients provided written informed 
consent for the TAVI procedure. NICOR has support under section 251 of the NHS 
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Act 2006. Under NHS research governance arrangements, formal ethical approval 
was not required for this study. 
 
Statistical Analysis 
Statistical analysis was performed using SPSS V.23.0 statistical software (SPSS Inc, 
Chicago, Illinois, USA). Categorical data are presented as percentages and 
comparisons between groups were performed by the chi-squared test or the Fisher’s 
exact test. Numerical data are presented as median (interquartile range) and 
comparisons performed using the Mann-Whitney-U test. All the variables used in the 
analysis had <5% of the values missing and were therefore treated as missing 
completely at random with case-wise deletion. Logistic regression analysis was used 
to assess the relationship between pre- and peri-operative factors and the need for 
dialysis post-procedure and in-patient mortality with the results expressed as an odds 
ratio (OR) with 95% confidence intervals (95% CI). Time-to-event data analysis for 
cumulative mortality at 30-days and 4-years were performed using the Cox 
Proportional hazards model and the results expressed as a Hazard Ratio (HR) with 
95% CI. Multivariable models were adjusted for gender, age, left ventricular ejection 
fraction less than 30%, New York Heart Association functional status 3-4, peripheral 
vascular disease, known coronary artery disease, pre-existing atrial fibrillation, 
previous cardiac surgery, diabetes mellitus, chronic obstructive pulmonary disease, 
previous stroke, previous myocardial infarction, ascending aortic calcification, valve 
manufacturer (Medtronic, Edwards, other) non-transfemoral route, use of general 
anaesthetic, moderate-severe aortic regurgitation, myocardial infarction before 
discharge, stroke before discharge, cardiac tamponade, conversion to open surgery 
and major vascular complication. Kaplan-Meier survival curves were drawn to assess 
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differences between groups for the time to an event data and estimate mortality rates. 
Comparisons were made using the log-rank statistic. For all tests, a value of P<0.05 
was considered significant. 
 
RESULTS 
Patient characteristics 
Baseline demographic characteristics and risk factors of the study population divided 
by need for dialysis before or after TAVI are presented in Table 1. Of the 6464 
patients included in the study, 117 (1.8%) were on dialysis before the TAVI 
procedure with the proportion of patients remaining constant over time (Figure 1; 
P=0.704). Over the whole study period, two hundred and two (3.1%) patients required 
dialysis for the first time after the TAVI procedure. The proportion of patients newly 
requiring dialysis post-TAVI has been declining over time with (Figure 1; P<0.001). 
 
Factors associated with new requirement for dialysis after TAVI procedure 
In a univariable analysis, the Logistic EuroSCORE (European System for Cardiac 
Operative Risk Evaluation) was associated with new requirement for dialysis after 
TAVI (OR 1.02 95% CI 1.01-1.03; P<0.001). The univariable and multivariable 
individual pre-procedural and peri-procedural factors associated with the new need for 
dialysis are shown in Table 2. In the multivariable analysis the pre-procedural factors 
were a lower eGFR (as a continuous variable), year of operation, a left ventricular 
ejection fraction less than 30% and a diagnosis of diabetes mellitus. Procedural 
factors associated with a new requirement for dialysis were a non-transfemoral 
approach, conversion to open surgery and use of an Edwards valve rather than a 
Medtronic valve. Having moderate to severe aortic regurgitation after the procedure 
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was also associated with an increased risk for new dialysis after TAVI. The year of 
procedure was inversely associated with the risk of requiring dialysis after TAVI in 
both univariable and multivariable analyses (Table 2). Excluding cases performed 
2007-2008 made no appreciable difference to the result. In a model incorporating the 
year of procedure and the logistic EuroSCORE as a composite measure of patient co-
morbidity only, the year of procedure remained inversely associated with the need for 
dialysis after TAVI (OR 0.85 95% CI 0.79-0.91; P<0.001). 
 
Stages of CKD were grouped into moderate-advanced CKD, stages 3b-5 (OR 4.27 
95% CI 2.93-6.22; P<0.001), and advanced CKD, stages 4-5  (OR 4.02 95% CI 2.97-
5.43; P<0.001) and entered separately into the model replacing eGFR as a continuous 
variable. Both were independently associated with the need for dialysis post-TAVI 
and did not significantly alter the model.  
 
The finding that use of the Edwards valve was associated with a higher risk of 
requiring dialysis after TAVI was unexpected. We, therefore, explored this 
relationship further. Patients receiving an Edwards valve were more co-morbid with 
an increased risk profile as evaluated by the logistic EuroSCORE (Supplementary 
Table 1). The proportion of patients with the variables found to be associated with the 
new need for dialysis after TAVI (Table 2) are presented in Supplementary Table 1. 
Proportionately many more patients receiving an Edwards valve had a non-
transfemoral approach (34.2% v. 14.9%: P<0.001) and more required conversion to 
open surgery (1.3% v. 0.5%: P=0.004). However, proportionately fewer patients 
receiving an Edwards valve had moderate-to-severe aortic regurgitation after the 
procedure (4.8% v. 12.5%; P<0.001). Given that the non-transfemoral approach has 
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been consistently found to be associated with worse outcomes after TAVI and that the 
decision-making process for the choice of approach is difficult to quantify objectively, 
the logistic regression analyses were repeated excluding patients who underwent a 
non-femoral approach. The full univariable and multivariable associations in this 
model are shown in Supplementary Table 2. Use of an Edwards valve remained 
associated with an increased risk of requiring dialysis after the procedure (OR 1.85 
95% CI 1.09-3.14; P=0.006). 
 
Dialysis requirements and mortality 
The median follow-up period was 625 (268-1208) days. Overall, 2486 (37%) patients 
died during the follow-up period. In total, 314 (4.9%) patients died during the hospital 
admission. Two hundred and twenty-three (3.7%) patients with no dialysis 
requirement, 9 (7.8%) patients on dialysis before the procedure and 82 (40.6%) 
patients requiring dialysis after TAVI died in hospital (P<0.001).  The Kaplan-Meier 
cumulative survival curves are shown in Figure 2. The Kaplan-Meier mortality 
estimates in patients with no dialysis requirements were 0.06, 0.07, 0.08, 0.16 and 
0.46 at 30-days, 60-days, 90-days, 1-year and 4-years respectively. These were 
significantly higher in patients requiring dialysis after the procedure at 0.35, 0.45, 
0.50, 0.64 and 0.84 at the same time-points (log rank P<0.001). Mortality was also 
higher in patients requiring dialysis after TAVI compared with those already on 
dialysis before the procedure (log rank P<0.001). 
 
 
The univariable and multivariable associations of dialysis requirement before or after 
TAVI with overall mortality at 30-days and at 4-years are presented in Table 3 and 
Supplementary Tables 3-4. Both dialysis requirements before and after TAVI were 
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independently associated with mortality at all time periods. For new dialysis 
requirement after TAVI, none of these associations were significantly affected by 
further adjustment for eGFR as a continuous variable, or by categorization of CKD 
stages to moderate-advanced CKD or advanced CKD. Valve make was not associated 
with mortality at any time period in the multivariable analyses (Supplementary Tables 
3-4). 
 
DISCUSSION 
Between 2007 and 2014 the incidence of AKI requiring new dialysis after TAVI in 
the UK was 3.1% but by 2013-2014 this had fallen to 2.1%. This decline was 
independent of patient co-morbidities and procedural characteristics recorded in the 
dataset. While most of the factors associated with the need for dialysis after TAVI 
were conventional risk factors for AKI, we found unexpectedly that use of an 
Edwards valve was independently associated with a greater need for new dialysis after 
the procedure. We have also shown that the new need for dialysis after a TAVI 
procedure is associated with higher mortality at 30-days, and 4-years after the 
procedure than that of patients on dialysis before TAVI and patients not requiring 
dialysis at all. 
 
With 6464 patients at risk, this study is by far the largest reporting the incidence rate 
of the need for dialysis after TAVI. This contrasts with a recent meta-analysis of AKI 
after TAVI which, although reporting on 24 studies (5971 patients), found only 13 
studies that gave the incidence of dialysis after TAVI with an at risk population of 
only 1058.(5) The need for dialysis in this study was 5.8%, which is much higher than 
the figure in our  analysis. This may, in part relate to the year of treatment. Our large 
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population has allowed us to examine the incidence of the need for new dialysis over 
time. This has decreased significantly between 2007 and 2014. The decline appears to 
be independent of recorded pre-procedural individual risk factors and of the logistic 
EuroSCORE as a comorbidity score. Excluding cases undertaken in the first 2 years to 
allow for the unusually high risk of the early cases and a potential learning curve did 
not affect this finding.  Although our study is not able to elucidate the reasons for this 
decline, possible explanations include changes in patient selection (with features not 
captured in the dataset), better procedural technique and better peri-procedural care 
optimising factors such as patient hydration, anaesthetics and sedation. 
 
In this study we have identified a number of factors that are well recognised to be 
associated with a higher risk of post-procedural AKI leading to dialysis including pre-
procedural kidney function and diabetes mellitus. With respect to procedural 
characteristics, in addition to a non-transfemoral approach we found that the use of an 
Edwards valve was associated with an increased risk of new dialysis requirement after 
TAVI. This association remained significant even when adjusted for co-morbidities. 
Furthermore, this association was still significant when procedures performed from 
the trans-femoral approach were considered in isolation (ie patients undergoing a non 
trans-femoral approach were excluded from the analysis). While the negative 
outcomes associated with use of a non-trans-femoral approach have been well 
described,(4,27,28) the association with the use of a particular valve or valve type has 
not. However, one retrospective, small study (118 patients) has also recently reported 
a higher rate of AKI associated with use of the Edwards valve compared with the 
Medtronic valve.(29) This association is difficult to explain given the excellent results 
reported by multiple investigators using this device.(27,30,31) It is notable that 
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although the Edwards valve was associated with an increased risk of dialysis 
requirement after TAVI it was not associated with increased mortality. While this 
study examines association and cannot  show causation, possible mechanistic 
explanations require consideration.  Possibilities include higher rates of micro-
embolisation to the kidneys during the procedure, transient reduced perfusion due to 
the brief period of hypotension that occurs during rapid pacing and possible 
differences in radiographic contrast dose during valve positioning. While the Edwards 
valve is loaded onto the deployment balloon in the descending aorta, this process does 
not onvolve significant contact with the aortic wall and seems unlikely to cause 
micro-embolization to renal arteries. The period of hypotension during rapid 
ventricular pacing is usually less than one minute but it is possible that this insult 
might precipitate AKI in patients, with already  compromised hemodynamics. 
Nevertheless, a previous study found no association between AKI and the number of 
pacing episodes.(18) Unfortunately, the TAVI registry does not collect data on 
contrast utilization. Finally, the influence of unmeasured risk factors such as frailty 
and co-morbid burden of disease that might be associated with use of an Edwards 
valve cannot be excluded. The wide experience and good results reported with the 
valve may have led operators to choose this valve in cases at higher risk for AKI. Low 
numbers of other balloon expandable valves used in the UK during this time mean 
that it is not possible to determine whether this association is present for other balloon 
expandable valves.  
 
The proportion of patients requiring dialysis for AKI after TAVI has decreased to a 
rate about  equal to that after SAVR.(5) Interestingly, a recent report of 133 patients 
(58% TAVI, 42% SAVR) has reported a greater risk of AKI in patients treated with 
16 
TAVI, compared to patients undergoing SAVR.(32) This may be a result of patient 
selection as well as differences in the procedural renal insults. 
 
In this study, we have shown that a new requirement for dialysis after TAVI was 
associated with a greater than six-fold increased risk of mortality at 30 days compared 
to non dialysis requiring controls while patients established on dialysis before TAVI 
had a greater than two-fold increased risk.  This difference suggests that the dialysis 
procedure itself accounts for only part of the excess mortality associated with the new 
use of dialysis.  However, there is almost certainly an inherent selection bias in 
patients accepted for TAVI already requiring dialysis treatment. This assertion is 
supported by the observation that this group of patients had the lowest median age. 
The risks associated with AKI are long term as evident from the increased risk of 
mortality present at 4-years. Whether interventions designed to prevent the need for 
dialysis after TAVI will improve outcomes requires further investigation.(33) 
 
Study strengths and weaknesses 
The strengths are the inclusion of all consecutive patients treated in the UK. This is a 
large number of patients with a wide range of risk profiles. Indeed our study is 6 times 
the size of a meta-analysis quantifying the risk of dialysis after a TAVI procedure. 
The UK TAVI Registry has captured every TAVI performed at all active units within 
the UK from the inception of the procedure in this country, and thus includes the 
entire “learning curve” and early experience of adopting centers without bias by 
center selection. The data collection shares the weaknesses of other national registry 
programs. There is a balance between the size of the dataset and the ability and/or 
willingness to collect it accurately.  Thus potentially informative data, involving the 
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need for prior balloon aortic valvuloplasty, contrast volume, recent contrast use for 
CT, angiography or angiography, bleeding and recovery of renal function after 
dialysis may not have been included. Other than mortality tracking, the accuracy and 
completeness of the data are self-reported and other than range checks and checks for 
internal validity, there are no external validation processes in place. Also, apart from 
mortality, later clinical and quality-of-life follow-up is limited. We investigated 
estimated rather than measured GFR in this study, and whilst this was (and will likely 
remain) a practical necessity we acknowledge the imperfection of the estimated 
measure.  As use of conscious sedation rather than general anaesthetic for TAVI 
occurred in large numbers only after 2014 we are unable to comment on the impact of 
this evolving approach.  
 
Conclusions 
Although the risk of requiring dialysis after TAVI appears to be decreasing, the very 
high mortality associated with this complication means that it warrants further 
investigation of potentially preventable risk factors.  
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Clinical Perspectives 
 
The reported rates of dialysis post TAVI differ widely and there is little information 
on outcomes after this complication. The incidence of dialysis requirement post-TAVI 
has been decreasing over time but is associated with a very high mortality. Further 
studies are needed to assess interventions and procedural/technique changes designed 
to lower the risk of significant acute kidney injury resulting in the need for dialysis 
post-TAVI. 
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Figure Titles and Legends 
 
 
Figure 1. Percentage of patients on dialysis before TAVI and with new 
requirement for dialysis after TAVI (2007-2014). 
 
The proportion of patients on dialysis undergoing TAVI has remained constant over 
the study time period whereas the proportion of patients requiring dialysis for the first 
time after the procedure has declined. 
 
 
Figure 2. Kaplan-Meier Curves for all-cause cumulative survival.  
 
Study patients are divided according to the need for dialysis either before or after 
TAVI (global log-rank test P<0.001). Patients requiring dialysis after TAVI had a 
higher mortality than both patients already on dialysis (pair-wise log-rank test 
P<0.001) and those with no dialysis requirement (pair-wise log-rank test P<0.001). 
Table 1: Clinical and procedural characteristics of the study population according 
to dialysis requirements before or after TAVI.  No dialysis Dialysis 
before 
Dialysis 
after 
*P value †P value
Number of TAVI procedures (%) ͸ͳͶͷ ȋͻͷ.ͳȌ ͳͳ͹ ȋͳ.ͺȌ ʹͲʹ ȋ͵.ͳȌ  
Male (%) ͵ʹͷͺ ȋͷ͵.ʹȌ ͹ͷ ȋ͸Ͷ.͹Ȍ ͳͳ͹ ȋͷ͹.ͻȌ Ͳ.ͳͻ͹ Ͳ.ʹͺͶ
Age (years) ͺ͵ ȋ͹͹-ͺ͹Ȍ ͹͹ ȋ͹ͳ-ͺʹȌ ͺ͵ ȋ͹͹-ͺ͹Ȍ Ͳ.ͻ͸ͳ <Ͳ.ͲͲͳ
Logistic EuroSCORE ͳ͹.ͺ ȋͳͳ.͸-ʹ͹.ͳȌ ʹͻ.Ͳ ȋͳͷ.ʹ-Ͷͳ.͹Ȍ ʹͳ.Ͳ ȋͳͶ.ͷ-͵ͷ.ͺȌ <Ͳ.ͲͲͳ Ͳ.Ͳͷ͸  
GFR (ml/min/1.73m2) Ͷͷ.ͳ ȋ͵͵.͹-͸Ͳ.ͺȌ N/A ͵ͳ.ͷ ȋʹʹ.ͳ-ͶͲ.ͶȌ <Ͳ.ͲͲͳ N/A
GFR categories/CKD stages (%)  
eGFR >60 ml/min/1.73m2   ͳͷͶͷ ȋʹͷ.ͳȌ N/A ͳ͵ ȋ͸.ͶȌ <Ͳ.ͲͲͳ N/A
 CKD stage 3 ͵Ͷͷͳ ȋͷ͸.ʹȌ N/A ͻͳ ȋͶͷ.ͲȌ  
CKD stage 4 ͻͻͳ ȋͳ͸.ͳȌ N/A ͺͲ ȋ͵ͻ.͸Ȍ  
CKD stage 5 ͺͺ ȋͳ.ͶȌ ͳͳ͹ ȋͳͲͲȌ ͳ͵ ȋ͸.ͶȌ  
Missing eGFR ͹Ͳ ȋͳ.ͳȌ N/A ͷ ȋʹ.ͷȌ  
  
LVEF<30% (%) ͷͶͷ ȋͺ.ͻȌ ͳ͹ ȋͳͶ.ͷȌ ͵Ͳ ȋͳͶ.ͻȌ Ͳ.ͲͲ͸ ͳ.ͲͲͲ
NYHA 3-4 (%) Ͷͻ͸ͺ ȋͺͳ.ʹȌ ͻ͸ ȋͺʹ.ͺȌ ͳ͹ʹ ȋͺͷ.ͳȌ Ͳ.͵͵ͺ Ͳ.͸͵ʹ
PVD (%) ͳͶʹͲ ȋʹ͵.ʹȌ ͵ʹ ȋʹ͹.͸Ȍ ͹ͺ ȋ͵ͺ.͸Ȍ <Ͳ.ͲͲͳ Ͳ.Ͳͷͳ
Any CAD (%) ʹͷͺͲ ȋͶʹ.͹Ȍ Ͷͻ ȋͶ͵.ͶȌ ͳͲͷ ȋͷʹ.ʹȌ Ͳ.ͲͲ͹ Ͳ.ͳͷͺ
Pre-existing AF (%) ͳͷͶ͹ ȋʹͷ.ͶȌ ͵Ͳ ȋʹͷ.ͻȌ ͷ͸ ȋʹ͹.͹Ȍ Ͳ.Ͷ͸Ͳ Ͳ.͹ͻ͵
Previous cardiac surgery (%) ͳͻ͵ͳ ȋ͵ͳ.͸Ȍ ͵͹ ȋ͵ͳ.͸Ȍ ͷͻ ȋʹͻ.ʹȌ Ͳ.ͶͻͲ Ͳ.͹ͲͶ
Diabetes mellitus (%) ͳ͵͹ͺ ȋʹʹ.ͷȌ ͵Ͷ ȋʹͻ.ͳȌ ͹Ͳ ȋ͵Ͷ.͹Ȍ <Ͳ.ͲͲͳ Ͳ.͵ʹͶ
COPD (%) ͳ͹͹ͻ ȋʹͻ.ͳȌ ͵ͺ ȋ͵ʹ.ͷȌ ͸ͺ ȋ͵͵.ͺȌ Ͳ.ͳͷ͸ Ͳ.ͻͲʹ
Previous stroke (%) ͳͲ͵ͺ ȋͳ͹.ͲȌ ʹͺ ȋʹ͵.ͻȌ Ͷ͵ ȋʹͳ.͵Ȍ Ͳ.ͳʹͺ Ͳ.ͷͺͲ
Previous MI (%) ͳ͵ͳ͹ ȋʹͳ.ͷȌ ʹͺ ȋʹ͵.ͻȌ ͷ͹ ȋʹͺ.ʹȌ Ͳ.Ͳ͵Ͳ Ͳ.Ͷ͵͵
AAC (%) ͳͲ͸͸ ȋͳ͹.ͶȌ ʹͺ ȋʹ͵.ͻȌ ͵ͺ ȋͳͺ.ͺȌ Ͳ.ͳͻͻ Ͳ.ͲͲͳ  
Procedural Characterisitics  
Valve Manufacturer  
Edwards (%) ͵Ͷʹͳ ȋͷ͸.ͲȌ ͸Ͷ ȋͷͶ.͹Ȍ ͳͶͻ ȋ͹͵.ͺȌ <Ͳ.ͲͲͳ Ͳ.ͲͲͳ
Medtronic (%) ʹͶ͹͹ ȋͶͲ.ͷȌ Ͷͺ ȋͶͳ.ͲȌ ͷͳ ȋʹͷ.ʹȌ  
Other (%) ʹͳ͸ ȋ͵.ͷȌ ͷ ȋͶ.͵Ȍ ʹ ȋͳ.ͲȌ  
Non-transfemoral approach (%) ͳͷʹͶ ȋʹͶ.ͺȌ ͵ͳ ȋʹ͸.ͷȌ ͻͻ ȋͶͻ.ͲȌ <Ͳ.ͲͲͳ <Ͳ.ͲͲͳ
General anaesthetic (%) ͷʹ͸Ͳ ȋͺͷ.ͻȌ ͳͲͲ ȋͺͷ.ͷȌ ͳͺͻ ȋͻ͵.͸Ȍ Ͳ.ͲͲͳ Ͳ.Ͳʹ͹
AR (moderate/severe) (%) ͶͷͲ ȋ͹.ͷȌ ͻ ȋ͹.ͺȌ ͵Ͷ ȋͳ͹.ͲȌ <Ͳ.ͲͲͳ Ͳ.Ͳʹ͸
MI before discharge (%) ͵Ͳ ȋͲ.ͷȌ Ͳ ȋͲȌ ͳ ȋͲ.ͷȌ Ͳ.ͻ͸ͺ ͳ.ͲͲͲ
Stroke before discharge (%) ͳ͵͹ ȋʹ.ʹȌ ʹ ȋͳ.͹Ȍ ͳʹ ȋͷ.ͻȌ Ͳ.ͲͲ͸ Ͳ.ͳͲͳ
Tamponade (%) ͻ͹ ȋͳ.͸Ȍ ʹ ȋͳ.͹Ȍ ͹ ȋ͵.ͷȌ Ͳ.ͲͶͻ Ͳ.Ͷͻͷ
Conversion to open surgery (%) ͷ͵ ȋͲ.ͻȌ Ͳ ȋͲȌ ͳͲ ȋͷ.ͲȌ <Ͳ.ͲͲͳ Ͳ.Ͳͳ͸
Major vascular complication (%) ͵͸͸ ȋ͸.ͲȌ Ͷ ȋ͵.ͶȌ ͳͺ ȋͺ.ͻȌ Ͳ.Ͳͻͺ Ͳ.Ͳ͹Ͳ *Comparison between group requiring dialysis after and group with no dialysis requirement.  
†Comparison between group requiring dialysis before TAV) and group with new dialysis requirement after TAV) Continuous values are summarized by median ȋinterquartile rangeȌ or mean ± standard deviation. Categorical values are summarized by count ȋpercentageȌ. 
Abbreviations; AAC= ascending aortic calcification,; AR=aortic regurgitation; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease;; CKD=chronic kidney disease; GFR=glomerular filtration fraction; LVEF=left ventricular ejection fraction; M)=myocardial infarction; N/A= non-applicable; NY(A=New York (eart Association; PVD=peripheral vascular disease; TAV)=transcatheter aortic valve implantation 
Table 2. Significant logistic regression multivariable associations of need for 
dialysis after procedure (patients on dialysis before procedure excluded from 
analysis). 
 
 Odds Ratio
 (95% CI) 
P-value
Pre-procedural characteristics  
eGFR (ml/min/1.73m2) Ͳ.ͻͷ ȋͲ.ͻͶ-Ͳ.ͻ͸Ȍ <Ͳ.ͲͲͳ
Left ventricular ejection fraction < 30% ͳ.ͷ͵ ȋͳ.Ͳͳ-ʹ.͵͵Ȍ Ͳ.ͲͶͺ 
Diabetes mellitus ͳ.͸͵ ȋͳ.ͳͻ-ʹ.ʹ͵Ȍ Ͳ.ͲͲʹ 
Year of procedure Ͳ.ͺͻ ȋͲ.ͺʹ-Ͳ.ͻ͸Ȍ Ͳ.ͲͲͶ  
Procedural and post-procedural features  
Valve manufacturer  
Medtronic ͳ  
Edwards ͳ.ͻʹ ȋͳ.͵ͷ-ʹ.͹ʹȌ <Ͳ.ͲͲͳ
Other Ͳ.͹ͳ ȋͲ.ͳ͹-ʹ.ͻ͹Ȍ Ͳ.͸͵͹ 
Non-transfemoral approach ʹ.Ͷ͸ ȋͳ.ͺͳ-͵.͵ͶȌ <Ͳ.ͲͲͳ
AR post-procedure (moderate/severe) ͵.Ͳͳʹ ȋͳ.ͻͻ-Ͷ.ͷ͹Ȍ <Ͳ.ͲͲͳ
Conversion to open surgery ͻ.ͷͻ ȋͶ.͵ͻ-ʹͲ.ͻ͸Ȍ <Ͳ.ͲͲͳ Abbreviations: AR=aortic regurgitation; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; eGFR=estimated glomerular filtration fraction; NY(A=New York (eart Association. 
 
Multivariable models adjusted for gender, age, left ventricular ejection fraction less than ͵Ͳ%, New York (eart Association functional status ͵-Ͷ, peripheral vascular disease, known coronary artery disease, pre-existing atrial fibrillation, previous cardiac surgery, diabetes mellitus, chronic obstructive pulmonary disease, previous stroke, previous myocardial infarction, ascending aortic calcification, valve manufacturer, non-transfemoral route, use of general anaesthetic, moderate-severe aortic regurgitation after procedure, myocardial infarction before discharge, stroke before discharge, cardiac tamponade, conversion to open surgery and major vascular complication. 
  
Table 3.  Cox-regression univariable and multivariable associations with 30-day, 
and 4-year mortality. 
 
Need for dialysis 
before  
or after TAVI 
Univariable
Analysis 
Multivariable 
Analysis 
 
 Hazard Ratio
(95% CI) 
P-
value 
Hazard Ratio  
(95% CI) 
P-
value 
At 30 Days 
No ͳ ͳ
Before ͳ.͹ͺ ȋͲ.ͻͳ-͵.ͶͷȌ Ͳ.ͲͻͲ ʹ.ʹͻ ȋͳ.ͳ͹-Ͷ.Ͷ͸Ȍ Ͳ.Ͳͳͷ
After ͻ.ʹͻ ȋ͹.ͳͷ-ͳʹ.ͲͺȌ <Ͳ.ͲͲͳ ͸.ͶͶ ȋͶ.ͺ͹-ͺ.ͷ͵Ȍ <Ͳ.ͲͲͳ
After* ͻ.ʹ͹ ȋ͹.ͳ͵-ͳʹ.ͲͷȌ <Ͳ.ͲͲͳ ͸.͸͵ ȋͷ.ͲͲ-ͺ.͹͹Ȍ <Ͳ.ͲͲͳ
 
At 4 Years 
No ͳ ͳ
Before ʹ.ͳ͸ ȋͳ.͸ͺ-ʹ.͹͹Ȍ <Ͳ.ͲͲͳ ʹ.Ͷ͸ ȋͳ.ͻͲ-͵.ͳͺȌ <Ͳ.ͲͲͳ
After Ͷ.Ͷ͸ ȋ͵.͹ͻ-ͷ.ʹͶȌ <Ͳ.ͲͲͳ ͵.ͷͶ ȋʹ.ͻͻ-Ͷ.ͳͻȌ <Ͳ.ͲͲͳ
After* Ͷ.Ͷͷ ȋ͵.͹ͺ-ͷ.ʹͶȌ <Ͳ.ͲͲͳ ͵.ʹͷ ȋʹ.͹͵-͵.ͺ͹Ȍ <Ͳ.ͲͲͳ
 Multivariable models adjusted for gender, age, left ventricular ejection fraction less than ͵Ͳ%, New York (eart Association functional status ͵-Ͷ, peripheral vascular disease, known coronary artery disease, pre-existing atrial fibrillation, previous cardiac surgery, diabetes mellitus, chronic obstructive pulmonary disease, previous stroke, previous myocardial infarction, ascending aortic calcification, valve manufacturer, non-transfemoral route, use of general anaesthetic, moderate-severe aortic regurgitation 
after procedure, myocardial infarction before discharge, stroke before discharge, cardiac tamponade, conversion to open surgery and major vascular complication.  *also adjusted for eGFR as a continuous variable with patients previously on dialysis excluded from the analysis.  Abbreviations: C)=confidence intervals, TAV)=trans-catheter aortic valve implantation  


